Tyra biosciences announces fda orphan drug designation for tyra-300 for the treatment of achondroplasia

Carlsbad, calif. , aug. 1, 2023 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to its lead precision medicine program, tyra-300, for the treatment of achondroplasia.
TYRA Ratings Summary
TYRA Quant Ranking